普雷托曼尼德可以显著增加血里瓦洛克萨班度 - - 一个案例报告
Dali Fan1, Teurai Chikura2, Sarah McCrostie2
1Department of Clinical Pharmacology, Christchurch Hospital, Te Whatu Ora Waitaha Canterbury, Christchurch, New Zealand. dali.fan@cdhb.health.nz.
European journal of clinical pharmacology
|July 2, 2025
概括
用于治疗多药耐药结核病的普雷托曼尼德 (Pretomanid) 通过抑制OAT3显著增加了里瓦洛克萨班水平,因此需要调整剂量. 这突出了与普雷托曼尼德和OAT3基质的潜在药物相互作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物相互作用 药物相互作用
- 临床药房 临床药房
背景情况:
- 作为直接的XA因子抑制剂,里瓦罗克萨班通过P-glycoprotein (P-gp) 和有机离子载体3 (OAT3) 通过清除.
- 针对多药耐药结核病 (MDR-TB) 的抗生素普雷托曼尼德是一种体外OAT3抑制剂.
- 本报告详细介绍了里瓦罗克萨班和普雷托曼尼德在MDR-TB患者之间的药理动力相互作用.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
921
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
921
Venous Thrombosis III: Interprofessional Care
27
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
27
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
259
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
259
Pharmacovigilance
1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
119
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
119


